Cancer treatments can lead to unpredictable adverse events, so a COVID-19–related measure allowing home infusion jeopardizes patient health and safety, according to the Community Oncology Alliance (COA).
Patient safety might be compromised because of home infusion regulatory changes brought about by the coronavirus disease 2019 (COVID-10) pandemic, according to the Community Oncology Alliance (COA), although other groups support the changes, which affect Medicare Part B beneficiaries.
The virus has altered healthcare not just for those with the novel virus, but also for patients with cancer or rare diseases. Providers are working overtime to accommodate the sudden need.
CMS has allowed numerous workforce changes to increase the capabilities and ranks of frontline healthcare workers during this emergency. In an additional change, added Thursday, CMS allowed doctors to work across state lines and nurse practitioners to perform medical exams in nursing homes.
Many providers are pleased with these new flexibilities, which include the use of telehealth.
CMS has also temporarily relaxed standards for home infusion therapy, physician contracts, remote monitoring, and coverage determinations
Last week, COA said of the health of patients with cancer could be jeopardized by some of these changes. COA said it opposes home infusion of chemotherapy, cancer immunotherapy, and supportive drugs related to cancer.
Home infusion “by a provider who may not be a trained oncology nurse and may not recognize or be prepared to treat any of the serious adverse reactions that frequently occur is of significant concern,” COA said, adding that many of the adverse events related to cancer treatment cannot be adequately monitored if patients are self-administering at home.
Visit AJMC.com for the full story.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.